Literature DB >> 20473929

VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Scott R Silva1, Kanika A Bowen, Piotr G Rychahou, Lindsey N Jackson, Heidi L Weiss, Eun Y Lee, Courtney M Townsend, B Mark Evers.   

Abstract

Carcinoid tumors are slow growing and highly vascular neuroendocrine neoplasms that are increasing in incidence. Previously, we showed that carcinoid tumors express vascular endothelial growth factor receptor 2 (VEGFR-2) in the epithelial compartment of carcinoid tumor sections; yet, its role is not completely understood. The purpose of our study was to: (i) assess the expression of VEGFR-2 in the novel human carcinoid cell line BON, (ii) to determine the role of PI3K/Akt signaling on VEGFR-2 expression and (iii) to assess the effect of VEGFR-2 on BON cell invasion, migration and proliferation. We found that, although VEGFR-2 is expressed in BON cells, reduction in VEGFR-2 expression actually enhanced proliferation, invasion, and migration of the BON cell line. Also, expression of VEGFR-2 was inversely related to PI3K signaling. Carcinoid liver metastases in mice demonstrated decreased VEGFR-2 expression. Furthermore, the expression of a truncated, soluble form of VEGFR-2 (sVEGFR-2), a protein demonstrated to inhibit cell growth, was detected in BON cells. The presence of VEGFR-2 in the epithelial component of carcinoid tumors and in the BON cell line suggests an alternate role for VEGFR-2, in addition to its well-defined role in angiogenesis. The expression of sVEGFR-2 may explain the inverse relationship between VEGFR-2 expression and PI3K/Akt signaling and the inhibitory effect VEGFR-2 has on BON cell proliferation, migration and invasion.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20473929      PMCID: PMC4104931          DOI: 10.1002/ijc.25441

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Authors:  Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 2.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

Review 3.  PI 3-kinase and cancer: changing accents.

Authors:  Peter K Vogt; Marco Gymnopoulos; Jonathan R Hart
Journal:  Curr Opin Genet Dev       Date:  2009-02       Impact factor: 5.578

Review 4.  PTEN mutation: many birds with one stone in tumorigenesis.

Authors:  Weijin Liu; Yonggang Zhou; Sven N Reske; Changxian Shen
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

5.  Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.

Authors:  Susan C Pitt; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  J Am Coll Surg       Date:  2009-05-01       Impact factor: 6.113

6.  PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway.

Authors:  Aliaksandr A Bulhak; Christian Jung; Claes-Göran Ostenson; Jon O Lundberg; Per-Ove Sjöquist; John Pernow
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-16       Impact factor: 4.733

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Development and characterization of a novel in vivo model of carcinoid syndrome.

Authors:  Lindsey N Jackson; L Andy Chen; Shawn D Larson; Scott R Silva; Piotr G Rychahou; Paul J Boor; Jing Li; Gilberto Defreitas; W Lane Stafford; Courtney M Townsend; B Mark Evers
Journal:  Clin Cancer Res       Date:  2009-03-31       Impact factor: 12.531

10.  Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition.

Authors:  Véronique Calleja; Michel Laguerre; Peter J Parker; Banafshé Larijani
Journal:  PLoS Biol       Date:  2009-01-20       Impact factor: 8.029

View more
  32 in total

1.  Association between genetic variations of vascular endothelial growth factor receptor 2 and glioma in the Chinese Han population.

Authors:  Hongyan Chen; Weimin Wang; Zhao Xingjie; Xiao Song; Weiwei Fan; Zhou Keke; Gong Chen; Yao Zhao; Ying Mao; Daru Lu
Journal:  J Mol Neurosci       Date:  2012-01-25       Impact factor: 3.444

Review 2.  Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

Authors:  Kein-Leong Yim
Journal:  Endocrine       Date:  2011-08-26       Impact factor: 3.633

Review 3.  Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.

Authors:  Giandomenico Roviello; Laura Zanotti; Sergio Venturini; Alberto Bottini; Daniele Generali
Journal:  Cancer Biol Ther       Date:  2016-07-14       Impact factor: 4.742

4.  Transient expression of anti-VEFGR2 nanobody in Nicotiana tabacum and N. benthamiana.

Authors:  Mostafa Modarresi; Mokhtar Jalali Javaran; Masoud Shams-Bakhsh; Sirous Zeinali; Mahdi Behdani; Malihe Mirzaee
Journal:  3 Biotech       Date:  2018-11-15       Impact factor: 2.406

Review 5.  Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.

Authors:  Omar Abdel-Rahman
Journal:  Tumour Biol       Date:  2014-09-18

6.  Correlation between VEGFR2 rs2071559 polymorphism and glioma risk among Chinese population.

Authors:  Guo-Zheng Xu; Ying Liu; Yi Zhang; Jing Yu; Bo Diao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.

Authors:  Jennifer A Chan; Robert J Mayer; Nadine Jackson; Paige Malinowski; Eileen Regan; Matthew H Kulke
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-09       Impact factor: 3.333

8.  Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors.

Authors:  Xavier M Keutgen; Kimberly J Ornell; Alyx Vogle; Olga Lakiza; Jelani Williams; Paul Miller; Katelyn S Mistretta; Namrata Setia; Ralph R Weichselbaum; Jeannine M Coburn
Journal:  Ann Surg Oncol       Date:  2021-06-05       Impact factor: 5.344

9.  Pulmonary atypical carcinoid in a patient with Cowden syndrome.

Authors:  Hiroaki Tsunezuka; Kaori Abe; Junichi Shimada; Masayoshi Inoue
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-29

Review 10.  Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.

Authors:  Namrata Vijayvergia; Arvind Dasari
Journal:  Curr Treat Options Oncol       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.